Should Novo Nordisk end up in direct competition with Ascendis Pharma on the growth hormone market, the Danish pharmaceutical giant has an arsenal ready, including a network of doctors and payers, says CEO Lars Fruergaard Jørgensen.
by ANDREAS LØNSTRUP, translated by daniel pedersen
The stage is being set for a battle of the Danes, with pharmaceutical giant Novo Nordisk in one corner and biotech firm Ascendis Pharma, which is on the upswing, in the other.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.